Brief: European Commission Grants Orphan Drug Designation For aTyr Pharma’s Efzofitimod For Treatment Of Sarcoidosis
18/01/2023 13:09
Jan 18 (Reuters) - aTyr Pharma Inc LIFE.O :
* EUROPEAN COMMISSION GRANTS ORPHAN DRUG DESIGNATION FOR
ATYR
PHARMA’S EFZOFITIMOD FOR TREATMENT OF SARCOIDOSIS
Source text for Eikon: ID:nGNXT1P1
Further company coverage: LIFE.O
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan